PenRad Technologies, Inc. is now part of Intelerad

Together we have expanded our offerings in mammography and lung analytics
 

Browse our solutions from PenRad

Optimize workflows for radiologists and boost health outcomes for patients

Combined with Intelerad’s robust medical imaging solutions, PenRad Technologies, Inc. brings excellent software for enhancing productivity for breast imaging and lung screening. The new partnership significantly expands the combined company’s ability to provide product offerings for mammography and lung analytics, optimizing workflows for radiologists and boosting health outcomes for patients.

PenRad’s three core product offerings – PenRad for breast imaging, PenLung for lung screening, and PenTrac for patient tracking and reporting – have a proven track record of eliminating overhead costs, decreasing liability exposure and increasing patient satisfaction for innovative enterprise systems and diagnostic imaging centers and facilities. With the company’s next-generation technology and dedicated client support, PenRad is leading the way in automated diagnostic radiology.

Women's Health

Enhance the health and well-being of your patients with image management

Powerful advances in mammography – like digital breast tomosynthesis – are boosting health outcomes for patients. In today’s world, it is crucial that providers can quickly and effectively access, share, and archive these studies for every patient.

PenRad

No EMR can match the value, insight, or support our mammography information system can provide

With a growing shortage of radiologists, technologists and IT staff, PenRad MIS offers productivity and financial gains along with many other benefits not fully recognized. This product significantly improves professional productivity, quality and revenue in mammography reporting workflow through automating tasks and eliminating duplication, secondary data input and transcription.

PenLung

Take control of burdens associated with LDCT

Lung screening presents a number of challenges for diagnostic imaging centers with Low Dose Computed Tomography (LDCT). Patients must be screened for eligibility requirements, and participating centers are required to upload pertinent exam information to a lung cancer screening registry in order to qualify for payment.

"The acquisition of PenRad is an exciting milestone for Intelerad. Our global team of dreamers and doers are committed to improving healthcare through innovative technology, which means delivering the best-in-class systems our industry needs to improve the overall health of all populations."
Mike Lipps
CEO, Intelerad

Learn how our expanded solutions can empower your healthcare organization

Start a Conversation

Fill out the form and our experts will show you how our scalable solutions will drive unparalleled results in your organization.